GO:0003223 ventricular compact myocardium morphogenesis: Trabeculation and Compaction, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0003223 describes the developmental process that generates and organizes the compact muscle layer of the ventricular heart wall.
• Trabeculation and compaction are coordinated by NOTCH1 and NRG1 signaling, which control cardiac jelly dynamics and the building plan of the ventricular wall.
• Additional sex combs-like (Asxl) family genes are required for normal cardiovascular development, including proper ventricular morphogenesis.
• Zbtb16 regulates cardiovascular progenitor fate plasticity through IGF2BP3-mediated mRNA stabilization, influencing ventricular wall formation.
• Trabecular and compact wall cardiomyocytes have equal force generation potential, indicating that compact myocardium is not simply a passive structural layer.
• Disruption of ventricular compaction is linked to non-compaction cardiomyopathy, a human disease characterized by a spongy ventricular wall.
Description
Ventricular compact myocardium morphogenesis (GO:0003223) is the biological process that generates and organizes the compact muscle layer of the cardiac ventricle. This process is essential for establishing a mechanically robust ventricular wall capable of sustaining systemic circulation. During development, the ventricular wall transitions from a predominantly trabecular (spongy) architecture to a compacted, multilayered myocardium, a transition that requires precise spatiotemporal regulation of signaling, gene expression, and cell behavior. Understanding this process is critical because defects in compaction underlie congenital and adult cardiomyopathies, including non-compaction of the ventricular myocardium. Research into GO:0003223 spans developmental biology, cardiovascular genetics, and regenerative medicine, with key roles identified for Notch1, Nrg1, Asxl family genes, and Zbtb16. This article synthesizes authoritative QuickGO annotation and verified PubMed literature to provide a research-grade overview of the genes, mechanisms, and experimental models relevant to ventricular compact myocardium morphogenesis.
ventricular compact myocardium morphogenesis At A Glance
| GO ID | GO:0003223 |
|---|---|
| GO term | ventricular compact myocardium morphogenesis |
| Ontology | biological_process |
| Synonym | none |
| Major function | Generation and organization of the compact ventricular muscle layer during heart development |
| Related process | Trabeculation and compaction of the ventricular wall |
| Key signaling pathways | NOTCH1 and NRG1 signaling; cardiac jelly dynamics |
| Associated genes | Notch1, Nrg1, Asxl1/2/3, Zbtb16, Igf2bp3 |
| Disease relevance | Non-compaction cardiomyopathy and other ventricular wall abnormalities |
What Is GO:0003223?
According to the Gene Ontology, GO:0003223 (ventricular compact myocardium morphogenesis) is defined as the process in which the anatomical structures of the compact cardiac ventricle muscle are generated and organized. In other words, it encompasses all cellular and molecular events that build and pattern the dense, outer myocardial layer of the ventricles, as opposed to the trabecular (spongy) inner layer.
Why Is ventricular compact myocardium morphogenesis Important in Cell Biology?
Ventricular compact myocardium morphogenesis is fundamental to heart function because the compact layer provides the structural integrity and contractile force needed for efficient blood ejection. Disruption of this process leads to non-compaction cardiomyopathy, a condition characterized by a spongy, hypertrabeculated ventricular wall with high morbidity. Studying GO:0003223 helps researchers understand congenital heart defects, identify therapeutic targets, and develop regenerative strategies for myocardial repair.
• Defects in ventricular compaction cause non-compaction cardiomyopathy, a serious human heart disease.
• The compact myocardium is essential for normal cardiac contractility and systemic circulation.
• NOTCH1 and NRG1 signaling coordinate trabeculation and compaction, providing mechanistic insight into ventricular wall building.
• Asxl family genes are required for normal cardiovascular development, linking epigenetic regulation to ventricular morphogenesis.
• Zbtb16 controls cardiovascular progenitor fate through IGF2BP3-mediated mRNA stabilization, affecting ventricular wall formation.
• Understanding compaction informs tissue engineering and regenerative approaches for myocardial repair.
• Animal models of non-compaction cardiomyopathy help identify disease mechanisms and potential therapies.
• GO:0003223 is a key annotation for interpreting cardiac developmental gene expression datasets.
What Happens During ventricular compact myocardium morphogenesis?
Initiation of trabeculation and cardiac jelly dynamics
In simple terms: The heart wall first forms a spongy inner layer, and the jelly between cell layers must be remodeled to allow compaction.
Ventricular compact myocardium morphogenesis begins with the establishment of trabeculae, finger-like projections of cardiomyocytes that increase surface area for nutrient exchange. Del Monte-Nieto et al. (2018) demonstrated that NOTCH1 and NRG1 signaling control cardiac jelly dynamics, which defines the building plan for trabeculation and subsequent compaction. This step is critical because proper jelly remodeling sets the stage for the outer compact layer to form.
Cardiomyocyte proliferation and differentiation
In simple terms: Heart muscle cells multiply and mature to build the dense outer wall.
During compaction, cardiomyocytes in the outer ventricular layer proliferate and differentiate to form a multilayered compact myocardium. Sedmera et al. (2000) described the developmental patterning of the myocardium, showing that compact layer formation involves coordinated cell division and differentiation. Disruption of this proliferation leads to persistent trabeculation and non-compaction.
Signaling pathways regulating compaction
In simple terms: Chemical signals tell the heart cells when to stop making spongy tissue and start making solid muscle.
NOTCH1 and NRG1 are central regulators of the trabeculation-to-compaction transition. Del Monte-Nieto et al. (2018) showed that NOTCH1 and NRG1 control cardiac jelly dynamics, which in turn defines the building plan for trabeculation and compaction. Additionally, Asxl family genes are required for normal cardiovascular development, including ventricular morphogenesis, and Zbtb16 influences cardiovascular progenitor fate through IGF2BP3-mediated mRNA stabilization.
Mechanical forces and functional maturation
In simple terms: The physical forces of beating help shape the heart wall into a solid layer.
Faber et al. (2022) demonstrated that trabecular and compact wall ventricular cardiomyocytes have equal force generation potential, indicating that mechanical forces are balanced during compaction. This suggests that the compact layer is not merely a passive structure but actively contributes to contractile function. Proper force generation is essential for the ventricle to pump blood effectively.
Completion of compaction and ventricular wall maturation
In simple terms: The heart wall finishes becoming a solid, thick muscle layer ready for life after birth.
The final stage of ventricular compact myocardium morphogenesis involves the consolidation of the compact layer into a mature, multilayered myocardium. Sedmera et al. (2000) described how developmental patterning of the myocardium leads to a mature ventricular wall. Failure of this process results in non-compaction cardiomyopathy, where the spongy architecture persists.
Key Genes Involved in GO:0003223 ventricular compact myocardium morphogenesis
The following genes have been experimentally implicated in ventricular compact myocardium morphogenesis or related cardiovascular development.
| Gene | Major Role | Research Relevance |
|---|---|---|
| Notch1 | Controls cardiac jelly dynamics and trabeculation/compaction building plan | Key signaling regulator; knockout models show defective ventricular wall formation |
| Nrg1 | Regulates cardiac jelly dynamics in coordination with NOTCH1 | Essential for trabeculation and compaction; studied in mouse models |
| Asxl1 | Required for normal cardiovascular development | Epigenetic regulator; Asxl family mutants show cardiovascular defects |
| Asxl2 | Required for normal cardiovascular development | Epigenetic regulator; Asxl family mutants show cardiovascular defects |
| Asxl3 | Required for normal cardiovascular development | Epigenetic regulator; Asxl family mutants show cardiovascular defects |
| Zbtb16 | Determines fate plasticity of cardiovascular progenitors via IGF2BP3-mediated mRNA stabilization | Transcription factor; influences progenitor differentiation and ventricular morphogenesis |
| Igf2bp3 | Stabilizes mRNA to regulate cardiovascular progenitor fate | RNA-binding protein; downstream of Zbtb16 |
| Nkx2-5 | Early cardiac transcription factor | Master regulator of heart development; mutations cause congenital heart defects |
| Tbx5 | Cardiac transcription factor | Involved in ventricular chamber specification and morphogenesis |
| Gata4 | Cardiac transcription factor | Regulates myocardial proliferation and differentiation |
| Mef2c | Cardiac transcription factor | Controls cardiomyocyte differentiation and ventricular wall formation |
| Hand1 | Cardiac transcription factor | Essential for ventricular morphogenesis |
| Hand2 | Cardiac transcription factor | Essential for ventricular morphogenesis |
| Nppa | Cardiac hormone marker | Marker of ventricular cardiomyocyte maturation |
| Nppb | Cardiac hormone marker | Marker of ventricular cardiomyocyte maturation |
| Myh7 | Beta-myosin heavy chain | Contractile protein; marker of compact myocardium |
| Actc1 | Alpha-cardiac actin | Contractile protein; essential for sarcomere function |
| Ttn | Titin | Sarcomeric protein; mutations cause cardiomyopathy |
How Is ventricular compact myocardium morphogenesis Regulated?
Ventricular compact myocardium morphogenesis is regulated by a network of signaling pathways and transcription factors. NOTCH1 and NRG1 signaling control cardiac jelly dynamics, which defines the building plan for trabeculation and compaction. Asxl family genes, which are epigenetic regulators, are required for normal cardiovascular development. Zbtb16 regulates cardiovascular progenitor fate plasticity through IGF2BP3-mediated mRNA stabilization. Additionally, mechanical forces generated by cardiomyocytes influence the compaction process, as trabecular and compact wall cells have equal force generation potential. These regulatory layers ensure that the ventricular wall matures into a compact, functional structure.
ventricular compact myocardium morphogenesis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| Notch1 | Non-compaction cardiomyopathy; defective trabeculation/compaction | Notch1 knockout mouse; cardiac-specific conditional KO |
| Nrg1 | Non-compaction cardiomyopathy; cardiac jelly defects | Nrg1 knockout mouse; inducible cardiac-specific KO |
| Asxl1 | Congenital heart defects; cardiovascular developmental abnormalities | Asxl1 knockout mouse; Asxl family mutants |
| Zbtb16 | Cardiovascular progenitor fate defects; ventricular morphogenesis abnormalities | Zbtb16 knockout mouse; progenitor-specific KO |
| Igf2bp3 | Impaired mRNA stabilization in cardiovascular progenitors | Igf2bp3 knockout mouse; conditional KO |
Non-compaction cardiomyopathy
Non-compaction of the ventricular myocardium is a cardiomyopathy characterized by a spongy, hypertrabeculated ventricular wall with deep intertrabecular recesses. This condition is thought to result from failure of ventricular compaction during development, making GO:0003223 directly relevant to its pathogenesis. Patients may present with heart failure, arrhythmias, or thromboembolic events. Research into the genetic and developmental basis of non-compaction is ongoing, with animal models helping to elucidate mechanisms.
Congenital heart defects
Disruption of genes required for ventricular compact myocardium morphogenesis, such as Asxl family genes and Zbtb16, can lead to congenital heart defects. These defects may include ventricular septal defects, hypoplastic ventricles, and other structural abnormalities. Understanding the molecular pathways governing compaction is essential for diagnosing and potentially treating these conditions.
Heart failure and arrhythmias
Impaired compaction can result in a weakened ventricular wall that is prone to heart failure and arrhythmias. The compact myocardium is critical for generating contractile force, and its malformation compromises cardiac output. Patients with non-compaction cardiomyopathy often develop progressive heart failure, highlighting the clinical importance of GO:0003223.
From ventricular compact myocardium morphogenesis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of Notch1 cause defective ventricular compaction? | Notch1 knockout mouse (conventional or cardiac-specific) |
| What is the role of Nrg1 in cardiac jelly dynamics? | Nrg1 conditional knockout mouse |
| Are Asxl family genes required for ventricular morphogenesis? | Asxl1/2/3 knockout mice |
| How does Zbtb16 regulate cardiovascular progenitor fate? | Zbtb16 knockout and overexpression mouse models |
| Do trabecular and compact cardiomyocytes differ in force generation? | Isolated cardiomyocyte force measurements in mouse models |
| What are the developmental stages of ventricular compaction? | Chick or mouse embryonic hearts; lineage tracing |
How to Study the ventricular compact myocardium morphogenesis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Histology (H&E, trichrome) | Tissue architecture, compact vs. trabecular layer thickness | Assessment of compaction defects in mutant hearts |
| Confocal microscopy | Cellular organization and protein localization | Visualization of myocardial layers and junction proteins |
| Lineage tracing | Origin and fate of cardiomyocytes | Tracking progenitor contribution to compact myocardium |
| RNA-seq | Global gene expression changes | Identifying pathways regulating compaction |
| Single-cell RNA-seq | Cell-type-specific expression profiles | Dissecting heterogeneity in compact vs. trabecular cells |
| Force measurement | Contractile force of isolated cardiomyocytes | Comparing trabecular and compact cell function |
| Echocardiography | In vivo cardiac function and wall motion | Phenotyping mouse models of non-compaction |
| Immunohistochemistry | Protein expression and localization | Detecting markers of compact myocardium |
Histology and imaging
Histological sections and imaging techniques such as confocal microscopy are used to visualize the compact and trabecular layers of the ventricular wall. Sedmera et al. (2000) used developmental patterning studies to describe myocardial architecture. These methods allow researchers to assess compaction defects in mutant hearts.
Genetic lineage tracing
Lineage tracing using Cre-lox systems can identify the origin and fate of cardiomyocytes contributing to the compact layer. This approach has been used to study cardiovascular progenitors and their differentiation. It helps determine whether specific gene mutations affect the contribution of progenitors to the compact myocardium.
Transcriptomics and RNA sequencing
RNA-seq can profile gene expression changes in compact versus trabecular myocardium. Del Monte-Nieto et al. (2018) used transcriptomic approaches to identify NOTCH1 and NRG1 target genes. This method is powerful for discovering novel regulators of compaction.
Functional assays for contractility
Force generation measurements in isolated cardiomyocytes, as performed by Faber et al. (2022), assess the functional capacity of compact and trabecular cells. These assays are critical for understanding how compaction affects cardiac pump function.
How CRISPR Can Be Used to Study GO:0003223 ventricular compact myocardium morphogenesis
Knockout
CRISPR knockout of genes such as Notch1, Nrg1, Asxl1, or Zbtb16 in mouse models or cardiomyocyte cell lines can recapitulate developmental defects in ventricular compaction. These models help determine whether a gene is essential for compact myocardium morphogenesis. For example, Notch1 knockout mice exhibit defective trabeculation and compaction.
Point Mutation
Introducing point mutations that mimic human variants in genes like Notch1 or Nrg1 can reveal specific residues required for signaling and compaction. This approach is useful for studying disease-associated mutations in non-compaction cardiomyopathy.
Knock-in
Knock-in of reporter genes (e.g., GFP) or epitope tags into endogenous loci such as Nkx2-5 or Mef2c allows visualization and tracking of compact myocardium cells. Tagged knock-in models facilitate chromatin immunoprecipitation and proteomic studies.
Overexpression
Overexpression of candidate genes like Zbtb16 or Igf2bp3 in cardiovascular progenitors can test sufficiency for driving compaction. This approach complements loss-of-function studies and helps establish causality.
How EDITGENE Supports ventricular compact myocardium morphogenesis Research
Researchers studying ventricular compact myocardium morphogenesis-related genes often need to determine whether a candidate gene is causally involved in the process or merely correlated with it. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such functional studies in relevant cell and animal models.
Contact EDITGENE today to design your custom CRISPR model for ventricular compact myocardium morphogenesis research.
Frequently Asked Questions About ventricular compact myocardium morphogenesis
What is ventricular compact myocardium morphogenesis?
It is the developmental process that generates and organizes the compact muscle layer of the ventricular heart wall, defined as GO:0003223.
What genes are involved in ventricular compact myocardium morphogenesis?
Key genes include Notch1, Nrg1, Asxl1/2/3, Zbtb16, and Igf2bp3, among others.
What is the role of NOTCH1 in ventricular compaction?
NOTCH1 controls cardiac jelly dynamics and defines the building plan for trabeculation and compaction.
How is ventricular compact myocardium morphogenesis related to disease?
Defects in this process cause non-compaction cardiomyopathy, a condition with a spongy ventricular wall.
What animal models are used to study ventricular compaction?
Mouse models with knockout or conditional alleles of Notch1, Nrg1, Asxl family genes, and Zbtb16 are commonly used.
What is non-compaction cardiomyopathy?
It is a heart disease characterized by a hypertrabeculated ventricular wall with deep recesses, often due to failed compaction.
How can CRISPR be used to study ventricular compact myocardium morphogenesis?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional testing of candidate genes in cardiomyocytes and animal models.
What methods are used to assess ventricular compaction?
Histology, imaging, lineage tracing, RNA-seq, and force measurements are commonly employed.
Is ventricular compact myocardium morphogenesis conserved across species?
Yes, key signaling pathways and genes are conserved between mouse, chick, and human heart development.
What are the research challenges in studying ventricular compact myocardium morphogenesis?
Challenges include the complexity of signaling networks, the need for conditional models, and the difficulty of isolating compact versus trabecular cardiomyocytes.
Conclusion
Ventricular compact myocardium morphogenesis (GO:0003223) is a critical developmental process that builds the dense outer muscle layer of the heart ventricle. Research has identified key roles for NOTCH1, NRG1, Asxl family genes, and Zbtb16 in regulating this process. Defects in compaction lead to non-compaction cardiomyopathy and other cardiac disorders, underscoring the clinical relevance of this GO term. Continued investigation using CRISPR-based models and advanced imaging will further elucidate the mechanisms and potential therapeutic targets for ventricular wall diseases.
References
- 1. McGinley AL et al.. 2014. Additional sex combs-like family genes are required for normal cardiovascular development.. Genesis 52(7):671-86 PMID: 24860998
- 2. Vizzardi E et al.. 2006. Non-compaction of the ventricular myocardium.. Heart Int 2(3-4):178 PMID: 21977268
- 3. Del Monte-Nieto G et al.. 2018. Control of cardiac jelly dynamics by NOTCH1 and NRG1 defines the building plan for trabeculation.. Nature 557(7705):439-445 PMID: 29743679
- 4. Wang W et al.. 2025. Zbtb16 determines the fate plasticity of cardiovascular progenitors through IGF2BP3-mediated mRNA stabilization.. Cell Rep 44(8):116127 PMID: 40779394
- 5. Faber JW et al.. 2022. Equal force generation potential of trabecular and compact wall ventricular cardiomyocytes.. iScience 25(11):105393 PMID: 36345331
- 6. Sedmera D et al.. 2000. Developmental patterning of the myocardium.. Anat Rec 258(4):319-37 PMID: 10737851
- 7. Domnitskaia TM et al.. 2006. [Non-compact left ventricular myocardium: current state of the problem].. Kardiologiia 46(8):63-8 PMID: 17047599
- 8. Engberding R et al.. 2010. Isolated non-compaction cardiomyopathy.. Dtsch Arztebl Int 107(12):206-13 PMID: 20386670
